Literature DB >> 19695009

International comparisons in valuing EQ-5D health states: a review and analysis.

Richard Norman1, Paula Cronin, Rosalie Viney, Madeleine King, Deborah Street, Julie Ratcliffe.   

Abstract

OBJECTIVE: To identify the key methodological issues in the construction of population-level EuroQol 5-dimensions (EQ-5D)/time trade-off (TTO) preference elicitation studies.
METHOD: This study involved three components. The first was to identify existing population-level EQ-5D TTO studies. The second was to illustrate and discuss the key areas of divergence between studies, including the international comparison of tariffs. The third was to portray the relative merits of each of the approaches and to compare the results of studies across countries.
RESULTS: While most articles report use of the protocol developed in the original UK study, we identified three key areas of divergence in the construction and analysis of surveys. These are the number of health states valued to determine the algorithm for estimating all health states, the approach to valuing states worse than immediate death, and the choice of algorithm. The evidence on international comparisons suggests differences between countries although it is difficult to disentangle differences in cultural attitudes with random error and differences as a result of methodological divergence.
CONCLUSIONS: Differences in methods may obscure true differences in values between countries. Nevertheless, population-specific valuation sets for countries engaging in economic evaluation would better reflect cultural differences and are therefore more likely to accurately represent societal attitudes.

Entities:  

Mesh:

Year:  2009        PMID: 19695009     DOI: 10.1111/j.1524-4733.2009.00581.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  62 in total

1.  Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.

Authors:  Evangelos Kalaitzakis; Maria Benito de Valle; Monira Rahman; Björn Lindkvist; Einar Björnsson; Roger Chapman; Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2015-10-15       Impact factor: 4.147

2.  Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.

Authors:  K Lien; V C Tam; Y J Ko; N Mittmann; M C Cheung; K K W Chan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

3.  Associations between living arrangements and health-related quality of life of urban elderly people: a study from China.

Authors:  Xiaojie Sun; Henry Lucas; Qingyue Meng; Yaoguang Zhang
Journal:  Qual Life Res       Date:  2010-09-30       Impact factor: 4.147

4.  A value set for the EQ-5D based on experienced health states: development and testing for the German population.

Authors:  Reiner Leidl; Peter Reitmeir
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

5.  Assessment of the Swedish EQ-5D experience-based value sets in a total hip replacement population.

Authors:  Szilárd Nemes; Kristina Burström; Niklas Zethraeus; Ted Eneqvist; Göran Garellick; Ola Rolfson
Journal:  Qual Life Res       Date:  2015-06-03       Impact factor: 4.147

6.  The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.

Authors:  Chen-Wei Pan; Hong-Peng Sun; Xingzhi Wang; Qinghua Ma; Yong Xu; Nan Luo; Pei Wang
Journal:  Qual Life Res       Date:  2014-12-25       Impact factor: 4.147

7.  EQ-5D-5L Valuation for the Malaysian Population.

Authors:  Asrul Akmal Shafie; Annushiah Vasan Thakumar; Ching Jou Lim; Nan Luo; Kim Rand-Hendriksen; Faridah Aryani Md Yusof
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

8.  Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.

Authors:  Liv Ariane Augestad; Kim Rand-Hendriksen; Ivar Sønbø Kristiansen; Knut Stavem
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

9.  Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise.

Authors:  Seungjin Bae; Soook Lee; Eun Young Bae; Sunmee Jang
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

10.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.